{
    "id": 12661,
    "fullName": "LMNA - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "LMNA-NTRK1 results from the fusion of LMNA and NTRK1, leading to activated kinase activity in nuclei of tumors (PMID: 26216294), transformation of cultured cells, and activation of MAPK signaling in a reporter assay (PMID: 30279230). LMNA-NTRK1 has been identified in soft-tissue sarcoma (PMID: 26216294), and MSI-high colorectal cancer (PMID: 30279230).",
            "references": [
                {
                    "id": 13140,
                    "pubMedId": 30279230,
                    "title": "Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30279230"
                },
                {
                    "id": 3689,
                    "pubMedId": 26216294,
                    "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26216294"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4000,
        "geneSymbol": "LMNA",
        "terms": [
            "LMNA",
            "CDCD1",
            "CDDC",
            "CMD1A",
            "CMT2B1",
            "EMD2",
            "FPL",
            "FPLD",
            "FPLD2",
            "HGPS",
            "IDC",
            "LDP1",
            "LFP",
            "LGMD1B",
            "LMN1",
            "LMNC",
            "LMNL1",
            "MADA",
            "PRO1"
        ]
    },
    "variant": "LMNA - NTRK1",
    "createDate": "10/02/2015",
    "updateDate": "04/05/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 3961,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing LMNA-NTRK1 were sensitive to AZ-23, resulting in inhibition of MAPK and PI3K pathway signaling (PMID: 24445538).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2678,
                "therapyName": "AZ-23",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3819,
                    "pubMedId": 24445538,
                    "title": "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24445538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15196,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing LMNA-NTRK1 were sensitive to treatment with Vitrakvi (larotrectinib) in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 29920189).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12810,
                    "pubMedId": 29920189,
                    "title": "Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29920189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15300,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment of a patient with a malignant fibrous histiocytoma of bone, harboring an LMNA-NTRK1 fusion, resulted in a near complete response, as evidenced by an 18-month disease free follow-up (PMID: 30134855).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3352,
                "name": "malignant fibrous histiocytoma of bone",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13003,
                    "pubMedId": 30134855,
                    "title": "A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30134855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3926,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Rozlytrek (entrectinib) treatment resulted in partial response for 3 months in a metastatic colorectal cancer patient harboring a LMNA-NTRK1 gene fusion (PMID: 26563355).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4297,
                    "pubMedId": 26563355,
                    "title": "Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26563355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11263,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 demonstrated a partial response when treated with Vitrakvi (larotrectinib) (PMID: 28578312).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13815,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a pediatric patients with soft tissue sarcoma harboring LMNA-NTRK1 fusion (PMID: 29606586; NCT02637687).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11285,
                    "pubMedId": 29606586,
                    "title": "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29606586"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3247,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with sarcoma harboring LMNA-NTRK1 had a marked improvement in multiple pulmonary metastases and was deemed a partial response by RECIST 1.1 when treated on a 4 week cycle of Vitrakvi (larotrectinib) (PMID: 26216294).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3689,
                    "pubMedId": 26216294,
                    "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26216294"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16323,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited growth of transformed cells expressing LMNA-NTRK1 in culture, led to tumor growth inhibition in cell line xenograft models (PMID: 30093503).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15718,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing LMNA-NTRK1 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15289,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a combined analysis of three trials, Vitrakvi (larotrectinib) treatment resulted in partial response in 60% (3/5) in patients with advanced solid tumors harboring an LMNA-NTRK1 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3927,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Rozlytrek (entrectinib) treatment resulted in partial response for 4 months in a colorectal cancer patient harboring a LMNA-NTRK1 gene fusion, followed by development of drug resistance that was attributed to acquired NTRK1 G595R and NTRK1 G667C mutations (PMID: 26546295).",
            "molecularProfile": {
                "id": 16584,
                "profileName": "LMNA - NTRK1 NTRK1 G595R NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4298,
                    "pubMedId": 26546295,
                    "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26546295"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11264,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 demonstrated progression after 6 months when treated with Vitrakvi (larotrectinib), and was found to also harbor NTRK1 G595R (PMID: 28578312).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11267,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated a partial response and decreased allele fraction of NTRK1 G595R, which was undetectable after two weeks when treated with LOXO-195 (PMID: 28578312).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10348,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing NTRK1 G595R in the context of LMNA-NTRK1 in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30093503).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8338,
                    "pubMedId": null,
                    "title": "TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants",
                    "url": "http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract"
                },
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15306,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 G595R was identified at disease progression in a patient with colon cancer harboring LMNA-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15269,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 F589L was identified at disease progression in a patient with cholangiocarcinoma harboring LMNA-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30928,
                "profileName": "LMNA - NTRK1 NTRK1 F589L"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated liver progression while on treatment with LOXO-195 and was found via cell-free DNA (cfDNA) testing to have acquired KRAS G12A, however, upon liver ablation and further LOXO-195 treatment, subsequent cfDNA testing revealed loss of KRAS G12A, but acquisition of KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33513,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18712,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R underwent prolonged treatment with LOXO-195, developing resistance in culture, and was subsequently found to have acquired KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19121,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of LOXO-195 and Mekinist (trametinib) compared to LOXO-195 treatment alone in colorectal cancer cells harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12D resulted in decreased cell viability in culture and reduced tumor growth in xenograft models (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and expressing KRAS G12A demonstrated resistance to treatment with Vitrakvi (larotrectinib) in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33519,
                "profileName": "LMNA - NTRK1 KRAS G12A"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R and expressing KRAS G12A demonstrated resistance to treatment with LOXO-195 in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19124,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12A demonstrated progression when treated with the combination of LOXO-195 and Mekinist (trametinib), however, a patient-derived xenograft (PDX) model for this patient demonstrated inhibition of tumor growth (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Tafinlar (dabrafenib), Mekinist (trametinib), and LOXO-195 in a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R and expressing BRAF V600E demonstrated tumor growth suppression and inhibition of Akt, Erk, and Mek signaling in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33932,
                "profileName": "LMNA - NTRK1 NTRK1 G595R BRAF V600E"
            },
            "therapy": {
                "id": 8909,
                "therapyName": "Dabrafenib + LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Tafinlar (dabrafenib), Mekinist (trametinib), and Vitrakvi (larotrectinib) in a colorectal cancer cell line harboring LMNA-NTRK1 and expressing BRAF V600E demonstrated tumor growth suppression and inhibition of Akt, Erk, and Mek signaling in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33932,
                "profileName": "LMNA - NTRK1 NTRK1 G595R BRAF V600E"
            },
            "therapy": {
                "id": 8908,
                "therapyName": "Dabrafenib + Larotrectinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 12816,
            "profileName": "LMNA - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19339,
                    "name": "Larotrectinib",
                    "profileName": "LMNA - NTRK1"
                },
                {
                    "id": 6915,
                    "name": "Trk Receptor Inhibitor (Pan)",
                    "profileName": "LMNA - NTRK1"
                }
            ]
        },
        {
            "id": 16584,
            "profileName": "LMNA - NTRK1 NTRK1 G595R NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27367,
            "profileName": "LMNA - NTRK1 NTRK1 G595R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30928,
            "profileName": "LMNA - NTRK1 NTRK1 F589L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33513,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33515,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33519,
            "profileName": "LMNA - NTRK1 KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33520,
            "profileName": "LMNA - NTRK1 KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33523,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33932,
            "profileName": "LMNA - NTRK1 NTRK1 G595R BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}